SAFETY DATA SHEET

Date of issue/Date of revision

: 23 October 2023

Version : 4

Ireland

pPG

SECTION 1: Identification of the substance/mixture and of the company/ undertaking

1.1 Product identifier

| Product name | : | SIGMAFAST 278 BASE BASE L |
|-------------------------------|---|---------------------------|
| Product code | : | 00346494 |
| Other means of identification | n | |

Not available.

| 1.2 Relevant identified uses | of the substance or mixture and uses advised against |
|----------------------------------|---|
| Product use | : Professional applications, Used by spraying. |
| Use of the substance/ mixture | : Coating. |
| Uses advised against | : Product is not intended, labelled or packaged for consumer use. |

1.3 Details of the supplier of the safety data sheet

PPG Coatings Belgium BV/SRL Tweemontstraat 104 B-2100 Deurne Belgium Telephone +32-33606311 Fax +32-33606435

e-mail address of person : Product.Stewardship.EMEA@ppg.com responsible for this SDS

1.4 Emergency telephone number

National advisory body/Poison Centre

National Poison Information Centre at Beaumont Hospital. Tel: +353 1 8092566, email: npicdublin@beaumont.ie <u>Supplier</u>

+31 20 4075210

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture

Product definition : Mixture Classification according to Regulation (EC) No. 1272/2008 [CLP/GHS] Flam. Liq. 3, H226 Skin Corr. 1B, H314 Eye Dam. 1, H318 Skin Sens. 1, H317

Repr. 2, H361fd STOT RE 2, H373 Aquatic Acute 1, H400

English (GB)

| Code | : 00346494 | Date of issue/Date of revision | : 23 October 2023 |
|------|------------|--------------------------------|-------------------|
| | | | |

SIGMAFAST 278 BASE BASE L

SECTION 2: Hazards identification

Aquatic Chronic 1, H410

The product is classified as hazardous according to Regulation (EC) 1272/2008 as amended.

See Section 16 for the full text of the H statements declared above.

See Section 11 for more detailed information on health effects and symptoms.

2.2 Label elements

| Hazard pictograms | | |
|---|---|---|
| Signal word | Danger | |
| Hazard statements | Flammable liquid and vapour. Causes severe skin burns and eye damage. May cause an allergic skin reaction. Suspected of damaging fertility. Suspected of damaging the unborn child. May cause damage to organs through prolonged or repeated exposure. Very toxic to aquatic life with long lasting effects. | |
| Precautionary statements | | |
| Prevention | Wear protective gloves, protective clothing and eye or face protection. Keep away fron heat, hot surfaces, sparks, open flames and other ignition sources. No smoking. Avoid release to the environment. Do not breathe vapour. | |
| Response | Collect spillage. | |
| Storage | Not applicable. | |
| Disposal | Dispose of contents and container in accordance with all local, regional, national and international regulations. | |
| | P280, P210, P273, P260, P391, P501 | |
| Hazardous ingredients | bis-[4-(2,3-epoxipropoxi)phenyl]propane 4-nonylphenol, branched crystalline silica, respirable powder (<10 microns) oxirane, mono[(C12-14-alkyloxy)methyl] derivs. Fatty acids, C14-18 and C16-18-unsatd., maleated maleic anhydride | |
| Supplemental label elements | Contains epoxy constituents. May produce an allergic reaction. Warning! Hazardous respirable droplets may be formed when sprayed. Do not breathe spray or mist. | 1 |
| Annex XVII - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles | Not applicable. | |
| Special packaging requirem | <u>nts</u> | |
| Containers to be fitted with child-resistant fastenings | Not applicable. | |
| Tactile warning of danger | Not applicable. | |

2.3 Other hazards

| English | (GB) |
|---------|------|
|---------|------|

| Code : 00346494 SIGMAFAST 278 BASE BASE | Date of issue/Date of revision : 23 October 2023 |
|---|--|
| SECTION 2: Hazards | identification |
| Product meets the criteria for PBT or vPvB | : This mixture does not contain any substances that are assessed to be a PBT or a vPvB. |
| Other hazards which do not result in classification | : Causes digestive tract burns. Prolonged or repeated contact may dry skin and cause irritation. |
| | May cause endocrine disruption. |

SECTION 3: Composition/information on ingredients

| 3.2 Mixtures | : Mixture | | | | |
|--|---|----------------|--|---|---------|
| Product/ingredient name | Identifiers | % by weight | Classification | Specific Conc. Limits, M-factors and ATEs | Туре |
| øs-[4-(2,3-epoxipropoxi) phenyl]propane | REACH #: 01-2119456619-26 EC: 216-823-5 CAS: 1675-54-3 Index: 603-073-00-2 | ≥10 - ≤25 | Skin Irrit. 2, H315 Eye Irrit. 2, H319 Skin Sens. 1, H317 Aquatic Chronic 2, H411 | Skin Irrit. 2, H315: C ≥ 5% Eye Irrit. 2, H319: C ≥ 5% | [1] |
| xylene | EC: 215-535-7 CAS: 1330-20-7 | ≥5.0 - ≤10 | Flam. Liq. 3, H226 Acute Tox. 4, H312 Acute Tox. 4, H332 Skin Irrit. 2, H315 Eye Irrit. 2, H319 STOT SE 3, H335 Asp. Tox. 1, H304 Aquatic Chronic 3, H412 | ATE [Dermal] = 1700 mg/kg ATE [Inhalation (vapours)] = 11 mg/l | [1] [2] |
| 4-nonylphenol, branched | REACH #: 01-2119510715-45 EC: 284-325-5 CAS: 84852-15-3 Index: 601-053-00-8 | ≥5.0 - ≤10 | Acute Tox. 4, H302 Skin Corr. 1B, H314 Eye Dam. 1, H318 Repr. 2, H361fd Aquatic Acute 1, H400 Aquatic Chronic 1, H410 | ATE [Oral] = 1300 mg/ kg M [Acute] = 10 M [Chronic] = 10 | [1] [3] |
| crystalline silica, respirable powder (<10 microns) | EC: 238-878-4 CAS: 14808-60-7 | ≥5.0 - <10 | STOT RE 1, H372 (inhalation) | - | [1] [2] |
| 1-methoxy-2-propanol | REACH #: 01-2119457435-35 EC: 203-539-1 CAS: 107-98-2 Index: 603-064-00-3 | ≥1.0 - ≤5.0 | Flam. Liq. 3, H226 STOT SE 3, H336 | - | [1] [2] |
| ethylbenzene | REACH #: 01-2119489370-35 EC: 202-849-4 CAS: 100-41-4 Index: 601-023-00-4 | ≥1.0 - ≤5.0 | Flam. Liq. 2, H225 Acute Tox. 4, H332 STOT RE 2, H373 (hearing organs) Asp. Tox. 1, H304 Aquatic Chronic 3, H412 | ATE [Inhalation (vapours)] = 17.8 mg/l | [1] [2] |
| oxirane, mono[(C12-14-alkyloxy)methyl] derivs. | REACH #: 01-2119485289-22 EC: 271-846-8 CAS: 68609-97-2 Index: 603-103-00-4 | ≥1.0 - ≤5.0 | Skin Irrit. 2, H315 Skin Sens. 1, H317 | - | [1] |
| English (GB) | | | Ireland | | 3/22 |

Code : 00346494

Date of issue/Date of revision

: 23 October 2023

SIGMAFAST 278 BASE BASE L

SECTION 3: Composition/information on ingredients

| trizinc bis(orthophosphate) | REACH #: 01-2119485044-40 EC: 231-944-3 CAS: 7779-90-0 Index: 030-011-00-6 | ≤1.0 | Aquatic Acute 1, H400 Aquatic Chronic 1, H410 | M [Acute] = 1 M [Chronic] = 1 | [1] |
|--|--|-------|---|---|---------|
| Fatty acids, C14-18 and C16-18-unsatd., maleated | REACH #: 01-2119978273-29 EC: 288-306-2 CAS: 85711-46-2 | ≤0.30 | Skin Irrit. 2, H315 Eye Irrit. 2, H319 Skin Sens. 1B, H317 | - | [1] |
| propylidynetrimethanol | REACH #: 01-2119486799-10 EC: 201-074-9 CAS: 77-99-6 | ≤0.30 | Repr. 2, H361 | - | [1] |
| maleic anhydride | REACH #: 01-2119472428-31 EC: 203-571-6 CAS: 108-31-6 Index: 607-096-00-9 | ≤0.10 | Acute Tox. 4, H302 Skin Corr. 1B, H314 Eye Dam. 1, H318 Resp. Sens. 1, H334 Skin Sens. 1A, H317 STOT RE 1, H372 (respiratory system) (inhalation) EUH071 See Section 16 for the full text of the H statements declared above. | ATE [Oral] = 400 mg/ kg Skin Sens. 1, H317: C ≥ 0.001% | [1] [2] |

There are no additional ingredients present which, within the current knowledge of the supplier and in the concentrations applicable, are classified as hazardous to health or the environment, are PBTs, vPvBs or Substances of equivalent concern, or have been assigned a workplace exposure limit and hence require reporting in this section.

Xylene: Several REACH registrations cover the REACH registered substance with xylene isomers, ethylbenzene (and toluene). The other REACH Registrations include: 01-2119555267-33 reaction mass of ethylbenzene and m-xylene and p-xylene, 01-2119486136-34 Aromatic hydrocarbons, C8, 01-2119539452-40 reaction mass of ethylbenzene and xylene.

<u>Type</u>

[1] Substance classified with a health or environmental hazard

[2] Substance with a workplace exposure limit

[3] Substance of equivalent concern

This mixture contains \geq 1% of titanium dioxide. The Annex VI classification of titanium dioxide does not apply to this mixture according to Note 10.

Occupational exposure limits, if available, are listed in Section 8.

SUB codes represent substances without registered CAS Numbers.

SECTION 4: First aid measures

| 4.1 Description of first a | id measures |
|----------------------------|--|
| Eye contact | : Check for and remove any contact lenses. Immediately flush eyes with running water for at least 15 minutes, keeping eyelids open. Seek immediate medical attention. |
| Inhalation | Remove to fresh air. Keep person warm and at rest. If not breathing, if breathing is irregular or if respiratory arrest occurs, provide artificial respiration or oxygen by trained personnel. |
| Skin contact | : Remove contaminated clothing and shoes. Wash skin thoroughly with soap and water or use recognised skin cleanser. Do NOT use solvents or thinners. |

| English (GB) Ireland | 4/22 |
|----------------------|------|
|----------------------|------|

| Conforms to Regulation (EC) No. 1907/2006 (REACH), Annex II, as amended by Commission Re | gulation (EU) |
|--|---------------|
| 2020/878 | |

| Code : 00346494 SIGMAFAST 278 BASE BAS | Date of issue/Date of revision: 23 October 2023E L |
|--|---|
| SECTION 4: First aid | l measures |
| Ingestion | : If swallowed, seek medical advice immediately and show the container or label. Keep person warm and at rest. Do NOT induce vomiting. |
| Protection of first-aiders | : No action shall be taken involving any personal risk or without suitable training. If it is suspected that fumes are still present, the rescuer should wear an appropriate mask or self-contained breathing apparatus. It may be dangerous to the person providing aid to give mouth-to-mouth resuscitation. Wash contaminated clothing thoroughly with water before removing it, or wear gloves. |
| 4.2 Most important sympton | ns and effects, both acute and delayed |
| Potential acute health effect | |
| Eye contact | Causes serious eye damage. |
| Inhalation | : No known significant effects or critical hazards. |
| Skin contact | : Causes severe burns. Defatting to the skin. May cause an allergic skin reaction. |
| Ingestion | : Corrosive to the digestive tract. Causes burns. |
| Over-exposure signs/symp | <u>toms</u> |
| Eye contact | : Adverse symptoms may include the following: |
| | pain watering redness |
| Inhalation | : Adverse symptoms may include the following: reduced foetal weight increase in foetal deaths skeletal malformations |
| Skin contact | : Adverse symptoms may include the following: pain or irritation redness dryness cracking blistering may occur reduced foetal weight increase in foetal deaths skeletal malformations |
| Ingestion | : Adverse symptoms may include the following: stomach pains reduced foetal weight increase in foetal deaths skeletal malformations |
| 4.3 Indication of any immedi | ate medical attention and special treatment needed |
| Notes to physician | Treat symptomatically. Contact poison treatment specialist immediately if large quantities have been ingested or inhaled. |
| Specific treatments | : No specific treatment. |
| SECTION 5: Firefigh | ting measures |
| 5.1 Extinguishing media Suitable extinguishing media | : Use dry chemical, CO ₂ , water spray (fog) or foam. |
| Unsuitable extinguishing media | : Do not use water jet. |

Code<th::</th>: 00346494Date of issue/Date of revision: 23 October 2023SIGMAFAST 278 BASE BASE L::

SECTION 5: Firefighting measures

| 5.2 Special | hazards | arising | from th | ne subs | tance or | mixture |
|-------------|---------|---------|---------|---------|----------|---------|
|-------------|---------|---------|---------|---------|----------|---------|

| Hazards from the substance or mixture | : Flammable liquid and vapour. Runoff to sewer may create fire or explosion hazard. In a fire or if heated, a pressure increase will occur and the container may burst, with the risk of a subsequent explosion. This material is very toxic to aquatic life with long lasting effects. Fire water contaminated with this material must be contained and prevented from being discharged to any waterway, sewer or drain. |
|--|---|
| Hazardous combustion products | : Decomposition products may include the following materials: carbon oxides halogenated compounds metal oxide/oxides |
| 5.3 Advice for firefighters | |
| Special precautions for fire-fighters | : Promptly isolate the scene by removing all persons from the vicinity of the incident if there is a fire. No action shall be taken involving any personal risk or without suitable training. Move containers from fire area if this can be done without risk. Use water spray to keep fire-exposed containers cool. |
| Special protective equipment for fire-fighters | : Fire-fighters should wear appropriate protective equipment and self-contained breathing apparatus (SCBA) with a full face-piece operated in positive pressure mode. Clothing for fire-fighters (including helmets, protective boots and gloves) conforming to European standard EN 469 will provide a basic level of protection for chemical incidents. |

SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures

| For non-emergency personnel | : No action shall be taken involving any personal risk or without suitable training. Evacuate surrounding areas. Keep unnecessary and unprotected personnel from entering. Do not touch or walk through spilt material. Shut off all ignition sources. No flares, smoking or flames in hazard area. Do not breathe vapour or mist. Provide adequate ventilation. Wear appropriate respirator when ventilation is inadequate. Put on appropriate personal protective equipment. |
|--------------------------------|--|
| For emergency responders | : If specialised clothing is required to deal with the spillage, take note of any information in Section 8 on suitable and unsuitable materials. See also the information in "For non-emergency personnel". |
| 6.2 Environmental precautions | : Avoid dispersal of spilt material and runoff and contact with soil, waterways, drains and sewers. Inform the relevant authorities if the product has caused environmental pollution (sewers, waterways, soil or air). Water polluting material. May be harmful to the environment if released in large quantities. Collect spillage. |
| 6.3 Methods and material for | containment and cleaning up |
| Small spill | : Stop leak if without risk. Move containers from spill area. Use spark-proof tools and explosion-proof equipment. Dilute with water and mop up if water-soluble. Alternatively, or if water-insoluble, absorb with an inert dry material and place in an appropriate waste disposal container. Dispose of via a licensed waste disposal contractor. |
| Large spill | : Stop leak if without risk. Move containers from spill area. Use spark-proof tools and explosion-proof equipment. Approach the release from upwind. Prevent entry into sewers, water courses, basements or confined areas. Wash spillages into an effluent treatment plant or proceed as follows. Contain and collect spillage with non-combustible, absorbent material e.g. sand, earth, vermiculite or diatomaceous earth and place in container for disposal according to local regulations. Dispose of via a licensed waste disposal contractor. Contaminated absorbent material may pose the same hazard as the spilt product. |

| Code : 00346494 SIGMAFAST 278 BASE BASE L | Date of issue/Date of revision | : 23 October 2023 | | |
|--|--------------------------------|-------------------|--|--|
| SECTION 6: Accidental release measures | | | | |

| 6.4 Reference to other | 1 | See Section 1 for emergency contact information. |
|------------------------|---|---|
| sections | | See Section 8 for information on appropriate personal protective equipment. See Section 13 for additional waste treatment information. |

SECTION 7: Handling and storage

The information in this section contains generic advice and guidance. The list of Identified Uses in Section 1 should be consulted for any available use-specific information provided in the Exposure Scenario(s).

7.1 Precautions for safe handling

| Protective measures | : Put on appropriate personal protective equipment (see Section 8). Persons with a history of skin sensitization problems should not be employed in any process in which this product is used. Avoid exposure - obtain special instructions before use. Avoid exposure during pregnancy. Do not handle until all safety precautions have been read and understood. Do not get in eyes or on skin or clothing. Do not breathe vapour or mist. Do not ingest. Avoid release to the environment. Use only with adequate ventilation. Wear appropriate respirator when ventilation is inadequate. Do not enter storage areas and confined spaces unless adequately ventilated. Keep in the original container or an approved alternative made from a compatible material, kept tightly closed when not in use. Store and use away from heat, sparks, open flame or any other ignition source. Use explosion-proof electrical (ventilating, lighting and material handling) equipment. Use only non-sparking tools. Take precautionary measures against electrostatic discharges. Empty containers retain product residue and can be hazardous. Do not reuse container. |
|--|--|
| Advice on general occupational hygiene | : Eating, drinking and smoking should be prohibited in areas where this material is handled, stored and processed. Workers should wash hands and face before eating, drinking and smoking. Remove contaminated clothing and protective equipment before entering eating areas. See also Section 8 for additional information on hygiene measures. |
| 7.2 Conditions for safe storage, including any incompatibilities | : Store between the following temperatures: 0 to 35°C (32 to 95°F). Store in accordance with local regulations. Store in a segregated and approved area. Store in original container protected from direct sunlight in a dry, cool and well-ventilated area, away from incompatible materials (see Section 10) and food and drink. Store locked up. Eliminate all ignition sources. Separate from oxidising materials. Keep container tightly closed and sealed until ready for use. Containers that have been opened must be carefully resealed and kept upright to prevent leakage. Do not store in unlabelled containers. Use appropriate containment to avoid environmental contamination. See Section 10 for incompatible materials before handling or use. |

7.3 Specific end use(s)

See Section 1.2 for Identified uses.

SECTION 8: Exposure controls/personal protection

The information in this section contains generic advice and guidance. The list of Identified Uses in Section 1 should be consulted for any available use-specific information provided in the Exposure Scenario(s).

8.1 Control parameters

Occupational exposure limits

Code : 00346494

Date of issue/Date of revision

: 23 October 2023

SIGMAFAST 278 BASE BASE L

SECTION 8: Exposure controls/personal protection

| Product/ingredient name | Exposure limit values |
|---|---|
| ₩ylene | NAOSH (Ireland, 5/2021). [xylene mixed isomers] Absorbed through skin. OELV-15min: 442 mg/m ³ 15 minutes. OELV-15min: 100 ppm 15 minutes. OELV-8hr: 221 mg/m ³ 8 hours. OELV-8hr: 50 ppm 8 hours. |
| crystalline silica, respirable powder (<10 microns) | |
| 1-methoxy-2-propanol | NAOSH (Ireland, 5/2021). Absorbed through skin. OELV-15min: 568 mg/m ³ 15 minutes. OELV-15min: 150 ppm 15 minutes. OELV-8hr: 375 mg/m ³ 8 hours. OELV-8hr: 100 ppm 8 hours. |
| ethylbenzene | NAOSH (Ireland, 5/2021). Absorbed through skin. OELV-15min: 884 mg/m ³ 15 minutes. OELV-15min: 200 ppm 15 minutes. OELV-8hr: 442 mg/m ³ 8 hours. OELV-8hr: 100 ppm 8 hours. |
| maleic anhydride | NAOSH (Ireland, 5/2021). Sensitization potential. OELV-8hr: 0.01 ppm 8 hours. Form: The Inhalable Fraction and Vapour note is used when a material exerts sufficient vapour pressure such that it may be present in both particle and vapour phases. |

Biological exposure indices

| Product/ingredient name | Exposure indices |
|-------------------------|--|
| x ylene | NAOSH (Ireland, 1/2011) [Xylene] BMGV: 1.5 g/g creatinine, methylhippuric acids [in urine]. Sampling time: end of shift - As soon as possible after exposure ceases. |
| ethylbenzene | NAOSH (Ireland, 1/2011) BMGV: Semi-quantitative, the biological analyte is an indicator of exposure to the substance but the quantitative interpretation of the measurement is ambiguous. These analytes should be used as a screening test if a quantitative test is not practical; or as a confirmatory test if the quantitative test is not specific and the origin of the determinant is in question., ethylbenzene [in endexhaled air]. Sampling time: not critical. BMGV: 0.7 g/g creatinine [Semi-quantitative, the biological analyte is an indicator of exposure to the substance but the quantitative interpretation of the measurement is ambiguous. These analytes should be used as a screening test if a quantitative test is not practical; or as a confirmatory test if the quantitative test is not specific and the origin of the determinant is in question.], mandelic acid and phenylglyoxylic acid [in urine]. Sampling time: end of shift at end of workweek. |

| Conforms to Regulation (EC) No. 1907/2006 (REACH), Annex II, as amended by Commission Regulation (EU) | |
|---|--|
| 2020/878 | |

| Code | : 00346494 | Date of issue/Date of revision | : 23 October 2023 |
|-------|------------|--------------------------------|-------------------|
| 0.014 | | | |

SIGMAFAST 278 BASE BASE L

SECTION 8: Exposure controls/personal protection

| Recommended monitoring | : Reference should be made to monitoring standards, such as the following: European |
|------------------------|---|
| procedures | Standard EN 689 (Workplace atmospheres - Guidance for the assessment of exposure |
| | by inhalation to chemical agents for comparison with limit values and measurement |
| | strategy) European Standard EN 14042 (Workplace atmospheres - Guide for the |
| | application and use of procedures for the assessment of exposure to chemical and |
| | biological agents) European Standard EN 482 (Workplace atmospheres - General |
| | requirements for the performance of procedures for the measurement of chemical |
| | agents) Reference to national guidance documents for methods for the determination |
| | of hazardous substances will also be required. |

DNELs

| Product/ingredient name | Туре | Exposure | Value | Population | Effects |
|---|--------------|-----------------------|--|--------------------|---|
| øís-[4-(2,3-epoxipropoxi) phenyl]propane | DNEL | Long term Inhalation | 12.25 mg/m ³ | Workers | Systemic |
| | DNEL | Short term Inhalation | 12.25 mg/m ³ | Workers | Systemic |
| | DNEL | Long term Dermal | 8.33 mg/kg bw/day | Workers | Systemic |
| | DNEL | Short term Dermal | 8.33 mg/kg bw/day | Workers | Systemic |
| | DNEL | Long term Dermal | 3.571 mg/kg bw/day | General | Systemic |
| | | C C | 000 | population | , |
| | | | | [Consumers] | |
| | DNEL | Short term Dermal | 3.571 mg/kg bw/day | General | Systemic |
| | | | 000 | population | |
| | | | | [Consumers] | |
| | DNEL | Long term Oral | 0.75 mg/kg bw/day | General | Systemic |
| | | | ······ | population | -, |
| | | | | [Consumers] | |
| | DNEL | Short term Oral | 0.75 mg/kg bw/day | General | Systemic |
| | | | ······································ | population | -) - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 |
| | | | | [Consumers] | |
| | DNEL | Long term Dermal | 89.3 µg/kg bw/day | General population | Systemic |
| | DNEL | Long term Oral | 0.5 mg/kg bw/day | General population | |
| | DNEL | Long term Dermal | 0.75 mg/kg bw/day | Workers | Systemic |
| | DNEL | Long term Inhalation | 0.87 mg/m ³ | General population | |
| | DNEL | Long term Inhalation | 4.93 mg/m ³ | Workers | Systemic |
| kylene | DNEL | Short term Inhalation | 260 mg/m ³ | General population | |
| Giene | DNEL | Short term Inhalation | 260 mg/m ³ | General population | |
| | DNEL | Long term Dermal | 125 mg/kg bw/day | General population | |
| | DNEL | Long term Inhalation | 65.3 mg/m ³ | General population | |
| | DNEL | Long term Oral | 12.5 mg/kg bw/day | General population | |
| | DNEL | Long term Inhalation | 221 mg/m ³ | Workers | Systemic |
| | DNEL | Short term Inhalation | | Workers | |
| | | | 442 mg/m ³ | | Systemic |
| | DNEL DNEL | Long term Inhalation | 221 mg/m ³ | Workers | Local |
| | DNEL | Short term Inhalation | 442 mg/m ³ | Workers | Local |
| | | Long term Dermal | 212 mg/kg bw/day | Workers | Systemic |
| | DNEL | Long term Inhalation | 65.3 mg/m ³ | General population | |
| | DNEL | Short term Inhalation | 260 mg/m ³ | General population | |
| | DNEL | Short term Inhalation | 260 mg/m ³ | General population | • |
| | DNEL | Long term Inhalation | 221 mg/m ³ | Workers | Local |
| | DNEL | Long term Oral | 12.5 mg/kg bw/day | General population | |
| | DNEL | Long term Inhalation | 65.3 mg/m ³ | General population | |
| | DNEL | Long term Dermal | 125 mg/kg bw/day | General population | • |
| | DNEL | Long term Dermal | 212 mg/kg bw/day | Workers | Systemic |
| | DNEL | Long term Inhalation | 221 mg/m ³ | Workers | Systemic |
| | DNEL | Short term Inhalation | 442 mg/m ³ | Workers | Local |
| | DNEL | Short term Inhalation | 442 mg/m ³ | Workers | Systemic |
| 1-nonylphenol, branched | DNEL | Long term Oral | 0.08 mg/kg bw/day | General population | |
| | DNEL | Short term Oral | 0.4 mg/kg bw/day | General population | Systemic |
| | | | | | |

Code : 00346494 SIGMAFAST 278 BASE BASE L Date of issue/Date of revision

: 23 October 2023

SECTION 8: Exposure controls/personal protection

| Differ Long term inhalation Differ Constraint | | DNEL | Long term Inhalation | 0.4 mg/m ³ | General population | Systemic |
|--|-----------------------------|-------|----------------------|-----------------------|--------------------|----------|
| DNEL Shoft term Inhalation DNEL 0.8 mg/m² 1 mg/kg bw/day General population General population DNEL Systemic Systemic 1-methoxy-2-propanol DNEL Snoft term Dermal DNEL 7.5 mg/kg bw/day General population Systemic Systemic Systemic 1-methoxy-2-propanol DNEL Snoft term Dermal DNEL 7.5 mg/kg bw/day General population Systemic Systemic 1-methoxy-2-propanol DNEL Long term Inhalation DNEL Snoft Systemic Systemic 1-methoxy-2-propanol DNEL Long term Inhalation DNEL Snoft Systemic Systemic 1-methoxy-2-propanol DNEL Long term Inhalation DNEL Systemic Systemic DNEL Long term Inhalation DNEL Systemic Systemic Systemic DNEL Long term Inhalation DNEL Systemic Systemic Systemic DNEL Long term Inhalation DNEL Systemic Systemic Systemic Oxfarate, monof (C12-14-al.kyloxy)methylj DNEL Long term Inhalation DNEL Smg/kg bw/day General population Systemic DNEL Long term Inhalation DNEL Long term Inhalation DN | | | | | | |
| DNEL Short term Inhalation 1 mg/m² Workers' Systemic 1-methoxy-2-propanol DNEL Long term Dermal 7.6 mg/kg bw/day General population Systemic 1-methoxy-2-propanol DNEL Soft term Dermal 7.6 mg/kg bw/day General population Systemic 1-methoxy-2-propanol DNEL Long term Orral 3.8 mg/kg bw/day General population Systemic DNEL Long term Inhalation 1.6 mg/kg bw/day General population Systemic DNEL Long term Inhalation 1.6 mg/kg bw/day General population Systemic DNEL Long term Inhalation 1.6 mg/kg bw/day General population Systemic DNEL Long term Inhalation 1.6 mg/kg bw/day Workers Systemic DNEL Long term Inhalation 1.6 mg/kg bw/day Workers Systemic Orkers DNEL Long term Dermal 1.6 mg/kg bw/day Workers Systemic Orkers DNEL Long term Dermal 1.6 mg/kg bw/day Workers Systemic Orkers | | | | | | |
| DNEL Long term Dermal 3.8 mg/kg bw/day General population Systemic 1-methoxy-2-propanol DNEL Shot term Dermal 7.5 mg/kg bw/day General population Systemic 1-methoxy-2-propanol DNEL Shot term Dermal 7.6 mg/kg bw/day General population Systemic 1-methoxy-2-propanol DNEL Long term Inhalation 3.9 mg/kg bw/day General population Systemic DNEL Long term Inhalation 3.9 mg/kg bw/day General population Systemic DNEL Long term Inhalation 3.6 mg/kg Workers Systemic DNEL Shot term Inhalation 55.3 mg/m² Workers Systemic DNEL Long term Inhalation 1.6 mg/kg bw/day General population Systemic DNEL Long term Inhalation 7.7 mg/kg bw/day Workers Systemic Oxfarae, mono[DNEL Long term Inhalation 7.6 mg/kg bw/day General population Systemic Oxfarae, mono[DNEL Long term Inhalation 0.8 mg/kg bw/day General population Systemic | | | | | | |
| 1-methoxy-2-propanol DNEL Long term Dermal 7.5 mg/kg bw/day Workers Systemic 1-methoxy-2-propanol DNEL Soft term Dermal 7.6 mg/kg bw/day General population Systemic DNEL Long term Inhalation 33 mg/kg bw/day General population Systemic DNEL Long term Inhalation 36 mg/kg bw/day General population Systemic DNEL Long term Inhalation 53.5 mg/m² Workers Systemic DNEL Short term Inhalation 553.5 mg/m² Workers Systemic DNEL Long term Inhalation 16 mg/kg bw/day General population Systemic DNEL Long term Inhalation 17 mg/m² Workers Systemic Oricla-14-alkyloxy)methyl DNEL Long term Draal 18 mg/kg bw/day Workers Systemic Cirla-14-alkyloxy)methyl DNEL Long term Draal 0.5 mg/kg bw/day General population Systemic Cirla-14-alkyloxy)methyl DNEL Long term Draal 1.8 mg/kg bw/day General population Systemic | | | | | | |
| DNEL Short term Dermal 7.6 mg/kg bw/day General oppulation Systemic 1-methoxy-2-propanol DNEL Long term Oral 13 mg/kg bw/day General oppulation Systemic DNEL Long term Dermal 13 mg/kg bw/day General oppulation Systemic DNEL Long term Inhalation 13 mg/kg bw/day General oppulation Systemic DNEL Long term Inhalation 53.5 mg/m² Workers Systemic DNEL Long term Inhalation 53.5 mg/m² Workers Systemic DNEL Long term Inhalation 16 mg/kg bw/day General oppulation Systemic DNEL Long term Inhalation 17 mg/m² Workers Systemic DNEL Long term Inhalation 16 mg/kg bw/day General oppulation Systemic Oxirane, mono[DNEL Long term Inhalation 42 mg/m² Workers Systemic C12-14-alkytoxymethyl] DNEL Long term Dermal 0.5 mg/kg bw/day General oppulation Systemic derivs. DNEL Long term Dermal 0 | | | | | | • |
| 1-methoxy-2-propanol DNEL Systemic Systemic 1-methoxy-2-propanol DNEL Long term Inhalation 33 mg/kg bw/day Workers Systemic DNEL Long term Inhalation DNEL Long term Inhalation 78 mg/kg bw/day General population Systemic DNEL Long term Inhalation 53.5 mg/m² Workers Systemic DNEL Long term Inhalation 15 mg/kg bw/day Workers Systemic DNEL Sont term Inhalation 15 mg/m² General population Systemic DNEL Long term Inhalation 16 mg/m² General population Systemic DNEL Long term Inhalation 77 mg/m³ Workers Systemic Oxirane, mono[DNEL Long term Inhalation 78 mg/kg bw/day Workers Systemic Oxirane, mono[DNEL Long term Inhalation 78 mg/kg bw/day Workers Systemic Oxirane, mono[DNEL Long term Inhalation 0.5 mg/kg bw/day General population Systemic Oxirane, mono[DNEL | | | | | | |
| 1-methoxy-2-propanol DNEL Long term (rhalation DNEL 33 mg/kg bw/day (application) General population Systemic Systemic Systemic ethylbenzene DNEL Long term Inhalation DNEL 13 mg/kg bw/day (application) General population Systemic Systemic Systemic ethylbenzene DNEL Long term Inhalation DNEL Sist term Inhalation DNEL Cong term Dermal DNEL Sist term Inhalation DNEL Sist term Inhalation DN | | | | | | |
| DNEL Long term Inhalation DNEL Long term Dermal 43.9 mg/m ² General population Systemic ethylbenzene DNEL Long term Inhalation 183 mg/kg bw/day Workers Systemic ethylbenzene DNEL Long term Inhalation 553.5 mg/m ² Workers Systemic ethylbenzene DNEL Long term Inhalation 553.5 mg/m ² General population Systemic oxirane, mono[DNEL Long term Inhalation 16 mg/kg bw/day Workers Systemic oxirane, mono[DNEL Long term Inhalation 180 mg/kg bw/day Workers Systemic oxirane, mono[DNEL Long term Inhalation 180 mg/kg bw/day Workers Systemic oxirane, mono[DNEL Long term Inhalation 0.5 mg/kg bw/day General population Systemic oxirane, mono[DNEL Long term Inhalation 0.5 mg/kg bw/day General population Systemic OMEL Long term Inhalation 0.5 mg/kg bw/day General population Systemic OMEL Long term Dermal | 1-methoxy-2-propanol | | | | | |
| DNEL Long term Dermal 78 mg/kg bw/day General population Systemic ethylbenzene DNEL Long term Inhalation 553.5 mg/m ² Workers Systemic ethylbenzene DNEL Long term Inhalation 553.5 mg/m ² Workers Systemic DNEL Long term Inhalation 1.6 mg/kg bw/day General population Systemic DNEL Long term Inhalation 1.6 mg/kg bw/day General population Systemic DNEL Long term Inhalation 1.6 mg/kg bw/day Workers Systemic Oxirane, mon0[DNEL Long term Inhalation 442 mg/m ² Workers Systemic Oxirane, mon0[DNEL Long term Inhalation 0.5 mg/kg bw/day General population Systemic Orl21-14-alkyloxy)methyl] DNEL Long term Inhalation 0.5 mg/kg bw/day General population Systemic derivs. DNEL Long term Inhalation 0.5 mg/kg bw/day General population Systemic DNEL Long term Oral 0.8 mg/kg bw/day General population Systemic | r-memoxy-z-propanor | | | | | |
| ethylbenzene DNEL DNEL DNEL DNEL DNEL DNEL DNEL DNEL | | | | 5 | | |
| ethylbenzene DNEL DNEL DNEL DNEL DNEL DNEL DNEL DNEL | | | | | | |
| ethylbenzeneDNEL DNELShort term Inhalation DNEL553.5 mg/m³ UnkersWorkersLocal SystemicethylbenzeneDNEL DNELLong term Inhalation DNEL16 mg/kg bw/day UnkersGeneral population Systemic General populationSystemic Systemic Ceneral populationSystemic Systemic Ceneral populationSystemic Systemic Ceneral populationSystemic Systemic Ceneral populationoxirane, mono[(C12-14-alkyloxy)methyl]DNEL DNELLong term Inhalation DMEL180 mg/kg bw/day UnkersWorkersLocal DMELoxirane, mono[(C12-14-alkyloxy)methyl]DNEL DMELLong term Inhalation DMEL0.5 mg/kg bw/day UnkersGeneral population Systemicoxirane, mono[(C12-14-alkyloxy)methyl]DNEL DMELLong term Oral0.5 mg/kg bw/day UnkersGeneral population SystemicDNEL trizinc bis(orthophosphate)DNEL DNEL Long term Inhalation DNEL Long term Inhalation DNEL Long term Inhalation DNEL Long term Oral0.5 mg/kg bw/day UnkersGeneral population Systemic Systemic Systemicfatty acids, C14-18 and DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Drahalation1.5 mg/kg bw/day UnkersGeneral population Systemic Systemic Systemic Systemicpropylidynetrimethanol DNEL Long term Drahalation DNEL Long term Drahalation DNEL Long term Drahalation DNEL Long term Drahalation1.5 mg/kg bw/day UnkersGeneral population Systemic Systemic Systemic Systemic Systemic Systemic Systemicpropyl | | | | | | |
| ethylbenzeneDNEL DNELShort term Inhalation DNEL Long term Inhalation DNEL Long term Inhalation DNEL Long term Inhalation DNEL Long term Inhalation DNEL Long term Inhalation DNEL Long term Inhalation DNEL DNEL Long term Inhalation DNEL DNEL DNEL Long term Inhalation DNEL DNEL DNEL Long term Inhalation | | | | | | • |
| ethylbenzene DNEL DNEL DNEL DNEL DNEL DNEL DNEL DNEL | | | | | | |
| DNEL DNEL Long term inhalation DNEL Long term inhalation DNEL Long term inhalation DNEL Long term inhalation DNEL Long term inhalation DMEL Long term inhalation DMEL Long term inhalation DMEL Long term inhalation DMEL Long term inhalation DMEL Long term inhalation DMEL | ethylbenzene | | | | | |
| DNEL DNEL Long term Inhalation DNEL Long term Inhalation DNEL Long term Inhalation DMEL Long term Inhalation DMEL Long term Inhalation DMEL Long term Inhalation DMEL Long term Oral77 mg/m³ 180 mg/kg bw/day Workers Using term Oral 0.87 mg/m³ WorkersWorkers Workers Using term Inhalation Systemicoxirane, mono[(C12-14-alkyloxy)methyl] derivs.DNEL DMEL Long term Oral DNEL Long term Inhalation DNEL Long term Inhalation DNEL Long term Inhalation DNEL Long term Inhalation DNEL Long term Oral0.5 mg/kg bw/day 0.87 mg/m³ Workers Usiter Usiter Usiter Systemic General population Systemic Syst | ethylbenzene | | - | | | |
| DNEL oxirane, mono[(C12-14-alkyloxy)methyl]Long term Inhalation DMEL Long term Inhalation DMEL Long term Inhalation DMEL Long term Inhalation DNEL Long term Dermal DNEL Long term Oral DNEL Long term Inhalation DNEL Long term Oral DNEL Long term Inhalation DNEL Long term I | | | | 0 | | |
| DNEL oxirane, mono[(C12-14-alkyloxy)methyl]DNEL DMEL Long term Inhalation DNEL Long term Oral29 mg/m³ 442 mg/m³ 0.5 mg/kg bw/day 0.5 mg/kg bw/day 0.5 mg/kg bw/day 0.6 mg/kg bw/day 0.87 mg/m³Workers Workers General population Systemic Workers Systemic Systemictrizinc bis(orthophosphate)DNEL DNEL Long term Inhalation DNEL Long term Dermal DNEL Long term Inhalation DNEL Long term Inhalation <br< td=""><td></td><td></td><td>0</td><td>9</td><td></td><td></td></br<> | | | 0 | 9 | | |
| oxirane, mono[(C12-14-alkyloxy)methyl]DMEL DMEL DMEL Long term OralLong term Oral DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Inhalation DNEL Long term Dermal DNEL Long term Inhalation DNEL Long | | | | | | |
| oxirane, mono[(C12-14-alkyloxy)methyl] derivs.DMEL DNEL Long term OralShort term Inhalation DNEL Long term Oral884 mg/m³ 0.5 mg/kg bw/dayWorkers General population SystemicSystemic Systemic(C12-14-alkyloxy)methyl] derivs.DNEL DNEL Long term Inhalation DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Oral DNEL Long term Dermal DNEL Long term Inhalation DNEL Long term In | | | | | | |
| oxirane, mono[(C12-14-aikyloxy)methyl] derivs.DNEL DNEL Long term Dermal DNEL Long term Inhalation DNEL Long term Dermal DNEL Long term Inhalation DNEL Long term Inhalation DNEL | | | 0 | | | |
| (C12-14-alkyloxy)methyl] derivs.DNEL DNEL Long term Inhalation DNEL Long term Dermal DNEL Long term Inhalation DNEL Long term Inhalation DNEL <td>ovirane monol</td> <td></td> <td></td> <td>3</td> <td></td> <td></td> | ovirane monol | | | 3 | | |
| DNEL DNEL Long term Dermal DNEL | (C12-14-alkyloxy)methyl] | | | 0.5 mg/kg bw/day | | Systemic |
| DNEL trizinc bis(orthophosphate)DNEL DNEL Long term Inhalation DNEL Long term Dermal DNEL Long term Inhalation DNEL Long term Inhal | denvs. | | Long term Dermal | 0.5 mg/kg bw/dgy | General population | Systemic |
| DNEL trizinc bis(orthophosphate)DNEL DNEL Long term Inhalation DNEL Long term Inhalation DNEL Long term Inhalation DNEL Long term Inhalation DNEL Long term Inhalation DNEL Long term Inhalation DNEL Long term Dermal DNEL Long term Inhalation DNEL Long term Inhalation DNEL <b< td=""><td></td><td></td><td></td><td></td><td></td><td></td></b<> | | | | | | |
| Itrizinc bis(orthophosphate)DNEL DNEL Long term Inhalation DNEL Long term Inhalation DNEL Long term Inhalation DNEL Long term Inhalation DNEL Long term Inhalation DNEL Long term Dermal DNEL Long term Dermal DNEL DNEL Long term Dermal DNEL Long term Dermal DNEL DNEL Long term Dermal DNEL DNEL Long term Dermal DNEL Long term Inhalation DNEL Long term Dranl DNEL Long term Dranl DNEL DNEL Long term Dermal DNEL Long term Dranl DNEL Long term Dranl DNEL DNEL Long term Dermal DNEL Long term Dermal <b< td=""><td></td><td></td><td>0</td><td>5</td><td></td><td></td></b<> | | | 0 | 5 | | |
| trizinc bis(orthophosphate)DNEL DNEL Long term Inhalation DNEL Long term Inhalation DNEL Long term Inhalation DNEL Long term Inhalation DNEL Long term Oral0.83 mg/kg bw/day 2.5 mg/m³ S mg/m³ S mg/m3 Workers General population Workers General population Systemic Systemic Systemic Systemic Systemic Systemic Systemic Systemic General populationSystemic Systemic Systemic Systemic Systemic SystemicFatty acids, C14-18 and C16-18-unsatd., maleatedDNEL DNEL Long term OralLong term Dermal 1.5 mg/kg bw/day 1.5 mg/kg bw/dayGeneral population Workers General population Workers General populationSystemic Systemic SystemicpropylidynetrimethanolDNEL DNEL Long term OralLong term Dermal 0.34 mg/kg bw/day 0.34 mg/kg bw/dayGeneral population Workers General population Systemic SystemicSystemic Systemic Systemicmaleic anhydrideDNEL DNEL Long term Inhalation DNEL Long term Inhalation0.34 mg/kg bw/day 0.34 mg/kg bw/day 0.34 mg/kg bw/day 0.44 mg/m3 Workers Workers DNEL Long term Inhalation DNEL Long term Oral DNEL Long term Oral DNEL Long term Oral DNEL Long term Oral DNEL DNEL Long term Oral DNEL DNEL Long term Oral DNEL DNEL Long term Oral DNEL DNEL DNEL Long term Oral DNEL DNE | | | 0 | | | |
| DNEL DNEL Long term Inhalation DNEL Long term Dermal DNEL Long term Inhalation DNEL Long term Inhalation DNEL< | trizinc his(orthonhosphate) | | | | | |
| Patty acids, C14-18 and C16-18-unsatd., maleatedDNEL Long term OralLong term Dermal Long term OralS mg/m3 83 mg/kg bw/day 1.5 mg/kg bw/day 1.5 mg/kg bw/dayWorkers General population Systemic Systemic Systemic SystemicpropylidynetrimethanolDNEL DNEL Long term OralLong term Oral DNEL Long term Dermal DNEL Long term Dermal1.5 mg/kg bw/day 3 mg/kg bw/day 0.34 mg/kg bw/day 0.34 mg/kg bw/day General population General population Systemic Systemic SystemicSystemic Systemic Systemicmaleic anhydrideDNEL DNEL Long term Inhalation DNEL Long term Inhalation DNEL | | | | | | |
| DNEL Fatty acids, C14-18 and C16-18-unsatd., maleatedDNEL Long term Dermal DNELLong term Dermal Long term Dermal DNEL83 mg/kg bw/day B3 mg/kg bw/day 1.5 mg/kg bw/dayGeneral population SystemicSystemic SystemicpropylidynetrimethanolDNEL DNEL Long term Dermal DNEL Long term Dermal1.5 mg/kg bw/day 3 mg/kg bw/day 0.34 mg/kg bw/dayGeneral population Systemic General populationSystemic Systemicmaleic anhydrideDNEL Long term Inhalation DNEL Long term Inhalation DNEL Long term Inhalation0.34 mg/kg bw/day 0.34 mg/kg bw/day 0.34 mg/kg bw/day 0.58 mg/m³General population Systemic General population Systemic General population Systemic DNEL Long term Inhalation DNEL Long term Oral DNEL Long term Dermal DNEL Long term Oral DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dermal | | | | | | |
| Fatty acids, C14-18 and C16-18-unsatd., maleatedDNEL Long term Oral83 mg/kg bw/day 1.5 mg/kg bw/dayWorkers General populationSystemicpropylidynetrimethanolDNEL Long term Dermal DNEL Long term Dermal1.5 mg/kg bw/day 3 mg/kg bw/dayGeneral population General populationSystemic Systemicmaleic anhydrideDNEL Long term Inhalation DNEL Long term Inhalation0.34 mg/kg bw/day 0.34 mg/kg bw/day 0.34 mg/kg bw/day General population General population SystemicSystemic Systemic Systemicmaleic anhydrideDNEL Long term Inhalation DNEL Long term Inhalation0.4 mg/m3 0.4 mg/m3Workers WorkersSystemic Systemic Cocal UorkersDNEL DNEL Long term Inhalation DNEL Long term Inhalation0.4 mg/m3 0.4 mg/m3Workers WorkersSystemic Systemic Local UorkersDNEL DNEL Long term Inhalation DNEL Long term Inhalation DNEL DNEL Long term Inhalation DNEL Long term Inhalation DNEL DNEL DNEL DNEL <b< td=""><td></td><td></td><td></td><td></td><td></td><td></td></b<> | | | | | | |
| Fatty acids, C14-18 and C16-18-unsatd., maleatedDNELLong term Oral1.5 mg/kg bw/dayGeneral populationSystemicpropylidynetrimethanolDNELLong term Dermal DNEL1.5 mg/kg bw/dayGeneral populationSystemicpropylidynetrimethanolDNELLong term Oral0.34 mg/kg bw/dayGeneral populationSystemicDNELLong term Oral0.34 mg/kg bw/dayGeneral populationSystemicDNELLong term Inhalation0.4 mg/m3General populationSystemicDNELLong term Inhalation0.94 mg/kg bw/dayGeneral populationSystemicDNELLong term Inhalation0.94 mg/kg bw/dayGeneral populationSystemicDNELLong term Inhalation0.94 mg/kg bw/dayWorkersSystemicDNELLong term Inhalation0.4 mg/m3WorkersSystemicDNELLong term Inhalation0.081 mg/m3WorkersLocalDNELShort term Inhalation0.081 mg/m3WorkersSystemicDNELLong term Inhalation0.05 mg/m3General populationSystemicDNELLong term Inhalation0.06 mg/kg bw/dayGeneral populationSystemicDNELLong term Dermal0.1 mg/kg bw/dayGene | | | | | | |
| C16-18-unsatd., maleated DNEL Long term Dermal 1.5 mg/kg bw/day General population Systemic propylidynetrimethanol DNEL Long term Oral 0.34 mg/kg bw/day General population Systemic DNEL Long term Dermal 0.34 mg/kg bw/day General population Systemic DNEL Long term Dermal 0.34 mg/kg bw/day General population Systemic DNEL Long term Dermal 0.34 mg/kg bw/day General population Systemic DNEL Long term Inhalation 0.58 mg/m³ General population Systemic DNEL Long term Inhalation 0.4 mg/m³ Workers Systemic DNEL Long term Inhalation 0.4 mg/m³ Workers Local DNEL Long term Inhalation 0.081 mg/m³ Workers Local DNEL Long term Inhalation 0.081 mg/m³ Workers Systemic DNEL Long term Inhalation 0.2 mg/m³ Workers Systemic DNEL Long term Inhalation 0.05 mg/m³ General population Systemic DNEL Long term Inhalation 0.05 mg/m³ < | Fatty acids C14-18 and | | | | | |
| DNEL propylidynetrimethanolDNEL DNEL Long term Dermal1.5 mg/kg bw/day 3 mg/kg bw/dayGeneral population SystemicSystemic SystemicpropylidynetrimethanolDNEL DNEL Long term Dermal0.34 mg/kg bw/day 0.34 mg/kg bw/dayGeneral population General populationSystemic SystemicDNEL DNEL DNEL DNEL Long term Inhalation0.34 mg/kg bw/day 0.34 mg/kg bw/dayGeneral population General populationSystemic Systemicmaleic anhydrideDNEL DNEL Long term Inhalation0.94 mg/kg bw/day 0.94 mg/kg bw/dayWorkersSystemic SystemicDNEL DNEL DNEL DNEL Long term Inhalation0.4 mg/m³ 0.4 mg/m³WorkersSystemic SystemicDNEL DNEL DNEL Long term Inhalation0.4 mg/m³ 0.081 mg/m³WorkersLocal LocalDNEL DNEL DNEL Long term Inhalation0.081 mg/m³ 0.2 mg/m³WorkersSystemic LocalDNEL DNEL DNEL DNEL Long term Inhalation0.2 mg/m³ 0.06 mg/kg bw/day 0.06 mg/kg bw/dayGeneral population Systemic General population Systemic DNEL Long term Inhalation0.2 mg/m³ 0.06 mg/kg bw/day General population General population Systemic General population Systemic Systemic DNEL Long term Dermal0.1 mg/kg bw/day 0.2 mg/kg bw/day General population General population Systemic Systemic Systemic Systemic Systemic DNEL DNEL DNEL Long term Dermal0.1 mg/kg bw/day 0.2 mg/kg bw/day General population General population Systemic Systemic Systemic Systemic Systemic Systemic Systemic Syst | | DITLE | | no mg/ng bw/day | | Cyclonic |
| propylidynetrimethanolDNEL DNEL DNEL DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL DNEL Long term Inhalation DNEL DNEL Long term Inhalation DNEL Long term Dermal DNEL Long term Dermal DNEL <td></td> <td>DNFI</td> <td>I ong term Dermal</td> <td>1.5 mg/kg bw/day</td> <td>General population</td> <td>Systemic</td> | | DNFI | I ong term Dermal | 1.5 mg/kg bw/day | General population | Systemic |
| propylidynetrimethanolDNELLong term Oral0.34 mg/kg bw/dayGeneral populationSystemicDNELLong term Dermal0.34 mg/kg bw/dayGeneral populationSystemicSystemicDNELLong term Inhalation0.58 mg/m³General populationSystemicDNELLong term Inhalation0.94 mg/kg bw/dayWorkersSystemicDNELLong term Inhalation3.3 mg/m³WorkersSystemicDNELLong term Inhalation0.4 mg/m³WorkersSystemicDNELLong term Inhalation0.4 mg/m³WorkersLocalDNELLong term Inhalation0.081 mg/m³WorkersLocalDNELLong term Inhalation0.081 mg/m³WorkersSystemicDNELLong term Inhalation0.2 mg/m³WorkersLocalDNELShort term Inhalation0.2 mg/m³WorkersSystemicDNELLong term Inhalation0.06 mg/kg bw/dayGeneral populationSystemicDNELLong term Inhalation0.08 mg/m³General populationSystemicDNELLong term Oral0.06 mg/kg bw/dayGeneral populationSystemicDNELLong term Oral0.1 mg/kg bw/dayGeneral populationSystemicDNELShort term Dermal0.1 mg/kg bw/dayGeneral populationSystemicDNELShort term Dermal0.2 mg/kg bw/dayGeneral populationSystemicDNELLong term Dermal0.2 mg/kg bw/dayGeneral populationSystemicDN | | | | | | |
| DNEL DNEL DNEL Long term Inhalation | propylidynetrimethanol | | 0 | | | |
| DNEL DNEL DNEL Long term Inhalation0.58 mg/m³ Ung term Dermal DNEL Long term InhalationGeneral population Systemic SystemicSystemic Systemicmaleic anhydrideDNEL DNEL Long term InhalationLong term Inhalation DNEL Long term Inhalation0.4 mg/m³ Ung term InhalationWorkers SystemicSystemic SystemicDNEL DNEL DNEL Long term Inhalation0.4 mg/m³ Ung term InhalationWorkers Ung term InhalationSystemic SystemicDNEL D | propynaynounnoundhor | | | | | |
| DNEL maleic anhydrideLong term Dermal DNEL Long term Inhalation DNEL Long term Dermal DNEL Long term | | | | | | |
| maleic anhydrideDNEL DNEL Long term Inhalation3.3 mg/m³ 0.4 mg/m³Workers WorkersSystemic SystemicDNEL DNEL< | | | | | | |
| maleic anhydrideDNEL DNELLong term Inhalation DNEL0.4 mg/m³ UorkersWorkers WorkersSystemic LocalDNEL DNELLong term Inhalation DNEL0.4 mg/m³ UorkersWorkers WorkersLocal LocalDNEL DNELLong term Inhalation DNEL0.081 mg/m³ UorkersWorkers VorkersLocal LocalDNEL DNELLong term Inhalation DNEL0.081 mg/m³ UorkersWorkers VorkersSystemic LocalDNEL DNELShort term Inhalation DNEL0.2 mg/m³ UorkersWorkers VorkersSystemic SystemicDNEL DNEL DNELLong term Inhalation DNEL0.05 mg/m³ UorkersGeneral population SystemicSystemic SystemicDNEL DNEL DNELLong term Oral DNEL DNEL0.06 mg/kg bw/day UorkersGeneral population SystemicSystemic SystemicDNEL DNEL DNEL DNELShort term Oral DNEL | | | 0 | | | |
| DNEL< | maleic anhvdride | | 0 | | | |
| DNELLong term Inhalation0.081 mg/m³WorkersLocalDNELLong term Inhalation0.081 mg/m³WorkersSystemicDNELShort term Inhalation0.2 mg/m³WorkersLocalDNELShort term Inhalation0.2 mg/m³WorkersSystemicDNELLong term Inhalation0.05 mg/m³General populationSystemicDNELLong term Oral0.06 mg/kg bw/dayGeneral populationSystemicDNELLong term Oral0.08 mg/m³General populationSystemicDNELShort term Oral0.1 mg/kg bw/dayGeneral populationSystemicDNELShort term Dermal0.1 mg/kg bw/dayGeneral populationSystemicDNELLong term Dermal0.2 mg/kg bw/dayGeneral populationSystemicDNELShort term Dermal0.1 mg/kg bw/dayGeneral populationSystemicDNELLong term Dermal0.2 mg/kg bw/dayWorkersSystemicDNELLong term Dermal0.2 mg/kg bw/dayWorkersSystemic | | | | | | |
| DNEL DNELLong term Inhalation Short term Inhalation0.081 mg/m³ UorkersWorkersSystemic LocalDNELShort term Inhalation0.2 mg/m³WorkersSystemicDNELShort term Inhalation0.2 mg/m³WorkersSystemicDNELLong term Inhalation0.05 mg/m³General populationSystemicDNELLong term Oral0.06 mg/kg bw/dayGeneral populationSystemicDNELLong term Oral0.1 mg/kg bw/dayGeneral populationSystemicDNELShort term Oral0.1 mg/kg bw/dayGeneral populationSystemicDNELShort term Dermal0.1 mg/kg bw/dayGeneral populationSystemicDNELLong term Dermal0.2 mg/kg bw/dayGeneral populationSystemicDNELShort term Dermal0.1 mg/kg bw/dayGeneral populationSystemicDNELLong term Dermal0.2 mg/kg bw/dayGeneral populationSystemicDNELLong term Dermal0.2 mg/kg bw/dayWorkersSystemicDNELLong term Dermal0.2 mg/kg bw/dayWorkersSystemicDNELLong term Dermal0.2 mg/kg bw/dayWorkersSystemicDNELLong term Dermal0.2 mg/kg bw/dayWorkersSystemic | | | | | | |
| DNELShort term Inhalation0.2 mg/m³WorkersLocalDNELShort term Inhalation0.2 mg/m³WorkersSystemicDNELLong term Inhalation0.05 mg/m³General populationSystemicDNELLong term Oral0.06 mg/kg bw/dayGeneral populationSystemicDNELLong term Inhalation0.08 mg/m³General populationSystemicDNELLong term Inhalation0.1 mg/kg bw/dayGeneral populationSystemicDNELShort term Oral0.1 mg/kg bw/dayGeneral populationSystemicDNELShort term Dermal0.1 mg/kg bw/dayGeneral populationSystemicDNELLong term Dermal0.2 mg/kg bw/dayGeneral populationSystemicDNELLong term Dermal0.2 mg/kg bw/dayGeneral populationSystemicDNELLong term Dermal0.2 mg/kg bw/dayWorkersSystemicDNELLong term Dermal0.2 mg/kg bw/dayWorkersSystemicDNELLong term Dermal0.2 mg/kg bw/dayWorkersSystemic | | | 0 | | | |
| DNELShort term Inhalation0.2 mg/m³WorkersSystemicDNELLong term Inhalation0.05 mg/m³General populationSystemicDNELLong term Oral0.06 mg/kg bw/dayGeneral populationSystemicDNELLong term Inhalation0.08 mg/m³General populationSystemicDNELShort term Oral0.1 mg/kg bw/dayGeneral populationSystemicDNELShort term Dermal0.1 mg/kg bw/dayGeneral populationSystemicDNELShort term Dermal0.1 mg/kg bw/dayGeneral populationSystemicDNELLong term Dermal0.2 mg/kg bw/dayGeneral populationSystemicDNELLong term Dermal0.2 mg/kg bw/dayGeneral populationSystemicDNELLong term Dermal0.2 mg/kg bw/dayWorkersSystemicDNELLong term Dermal0.2 mg/kg bw/dayWorkersSystemicDNELLong term Dermal0.2 mg/kg bw/dayWorkersSystemicDNELLong term Dermal0.2 mg/kg bw/dayWorkersSystemic | | | | | | |
| DNELLong term Inhalation0.05 mg/m³General populationSystemicDNELLong term Oral0.06 mg/kg bw/dayGeneral populationSystemicDNELLong term Inhalation0.08 mg/m³General populationSystemicDNELShort term Oral0.1 mg/kg bw/dayGeneral populationSystemicDNELShort term Dermal0.1 mg/kg bw/dayGeneral populationSystemicDNELShort term Dermal0.1 mg/kg bw/dayGeneral populationSystemicDNELLong term Dermal0.2 mg/kg bw/dayGeneral populationSystemicDNELShort term Dermal0.2 mg/kg bw/dayWorkersSystemicDNELLong term Dermal0.2 mg/kg bw/dayWorkersSystemicDNELLong term Dermal0.2 mg/kg bw/dayWorkersSystemic | | | | | | |
| DNEL DNELLong term Oral Long term Inhalation0.06 mg/kg bw/day 0.08 mg/m³General population General populationSystemic LocalDNEL DNELShort term Oral DNEL0.1 mg/kg bw/day 0.1 mg/kg bw/dayGeneral population General populationSystemic SystemicDNEL DNELShort term Dermal DNEL0.1 mg/kg bw/day 0.1 mg/kg bw/dayGeneral population General populationSystemic SystemicDNEL DNELLong term Dermal DNEL0.1 mg/kg bw/day 0.2 mg/kg bw/dayGeneral population SystemicSystemic SystemicDNEL DNELLong term Dermal Long term Dermal0.2 mg/kg bw/day 0.2 mg/kg bw/dayWorkers WorkersSystemic Systemic | | | | | | - |
| DNELLong term Inhalation0.08 mg/m³General populationLocalDNELShort term Oral0.1 mg/kg bw/dayGeneral populationSystemicDNELShort term Dermal0.1 mg/kg bw/dayGeneral populationSystemicDNELLong term Dermal0.1 mg/kg bw/dayGeneral populationSystemicDNELLong term Dermal0.2 mg/kg bw/dayGeneral populationSystemicDNELShort term Dermal0.2 mg/kg bw/dayWorkersSystemicDNELLong term Dermal0.2 mg/kg bw/dayWorkersSystemic | | | | | | |
| DNELShort term Oral0.1 mg/kg bw/dayGeneral populationSystemicDNELShort term Dermal0.1 mg/kg bw/dayGeneral populationSystemicDNELLong term Dermal0.1 mg/kg bw/dayGeneral populationSystemicDNELShort term Dermal0.2 mg/kg bw/dayWorkersSystemicDNELLong term Dermal0.2 mg/kg bw/dayWorkersSystemicDNELLong term Dermal0.2 mg/kg bw/dayWorkersSystemic | | | | | | |
| DNELShort term Dermal0.1 mg/kg bw/dayGeneral populationSystemicDNELLong term Dermal0.1 mg/kg bw/dayGeneral populationSystemicDNELShort term Dermal0.2 mg/kg bw/dayWorkersSystemicDNELLong term Dermal0.2 mg/kg bw/dayWorkersSystemicDNELLong term Dermal0.2 mg/kg bw/dayWorkersSystemic | | | | | | |
| DNELLong term Dermal0.1 mg/kg bw/dayGeneral populationSystemicDNELShort term Dermal0.2 mg/kg bw/dayWorkersSystemicDNELLong term Dermal0.2 mg/kg bw/dayWorkersSystemic | | | | | | • |
| DNELShort term Dermal0.2 mg/kg bw/dayWorkersSystemicDNELLong term Dermal0.2 mg/kg bw/dayWorkersSystemic | | | | | | |
| DNEL Long term Dermal 0.2 mg/kg bw/day Workers Systemic | | | | | | |
| English (GB) Ireland 10/22 | | | | | | • |
| | English (GB) | | | Ireland | | 10/22 |

Code : 00346494

Date of issue/Date of revision

: 23 October 2023

SIGMAFAST 278 BASE BASE L

SECTION 8: Exposure controls/personal protection

| | | | <u> </u> |
|---|---|---|----------|
| _ | ~ | _ | I C |
| | | | |

| Product/ingredient name | Туре | Compartment Detail | Value | Method Detail |
|---|------|------------------------|-----------------|--------------------------|
| pís-[4-(2,3-epoxipropoxi)phenyl] propane | - | Fresh water | 0.006 mg/l | Assessment Factors |
| | - | Marine water | 0.001 mg/l | Assessment Factors |
| | - | Fresh water sediment | 0.996 mg/kg dwt | Equilibrium Partitioning |
| | - | Marine water sediment | 0.1 mg/kg dwt | Equilibrium Partitioning |
| | - | Soil | 0.196 mg/kg dwt | Equilibrium Partitioning |
| | - | Sewage Treatment Plant | 10 mg/l | Assessment Factors |
| | - | Secondary Poisoning | 11 mg/kg | Assessment Factors |
| xylene | - | Fresh water | 0.327 mg/l | - |
| - | - | Marine water | 0.327 mg/l | - |
| | - | Sewage Treatment Plant | 6.58 mg/l | - |
| | - | Fresh water sediment | 12.46 mg/kg dwt | - |
| | - | Marine water sediment | 12.46 mg/kg dwt | - |
| | - | Soil | 2.31 mg/kg | - |
| 1-methoxy-2-propanol | - | Fresh water | 10 mg/l | Assessment Factors |
| | - | Marine water | 1 mg/l | Assessment Factors |
| | - | Sewage Treatment Plant | 100 mg/l | Assessment Factors |
| | - | Fresh water sediment | 41.6 mg/kg | Equilibrium Partitioning |
| | - | Marine water sediment | 4.17 mg/kg | Equilibrium Partitioning |
| | - | Soil | 2.47 mg/kg | Equilibrium Partitioning |
| ethylbenzene | - | Fresh water | 0.1 mg/l | Assessment Factors |
| | - | Marine water | 0.01 mg/l | Assessment Factors |
| | - | Sewage Treatment Plant | 9.6 mg/l | Assessment Factors |
| | - | Fresh water sediment | 13.7 mg/kg dwt | Equilibrium Partitioning |
| | - | Marine water sediment | 1.37 mg/kg dwt | Equilibrium Partitioning |
| | - | Soil | 2.68 mg/kg dwt | Equilibrium Partitioning |
| | - | Secondary Poisoning | 20 mg/kg | - |
| trizinc bis(orthophosphate) | - | Fresh water | 20.6 µg/l | Sensitivity Distribution |
| | - | Marine water | 6.1 µg/l | Sensitivity Distribution |
| | - | Sewage Treatment Plant | 100 µg/l | Assessment Factors |
| | - | Fresh water sediment | 117.8 mg/kg dwt | Sensitivity Distribution |
| | - | Marine water sediment | 56.5 mg/kg dwt | Equilibrium Partitioning |
| | - | Soil | 35.6 mg/kg dwt | Sensitivity Distribution |
| maleic anhydride | - | Fresh water | 0.1 mg/l | Assessment Factors |
| | - | Marine water | 0.01 mg/l | Assessment Factors |
| | - | Sewage Treatment Plant | 44.6 mg/l | Assessment Factors |
| | - | Fresh water sediment | 0.334 mg/kg dwt | Equilibrium Partitioning |
| | - | Marine water sediment | 0.033 mg/kg dwt | Equilibrium Partitioning |
| | - | Soil | 0.042 mg/kg dwt | Equilibrium Partitioning |

8.2 Exposure controls

Appropriate engineering controls

: Use only with adequate ventilation. Use process enclosures, local exhaust ventilation or other engineering controls to keep worker exposure to airborne contaminants below any recommended or statutory limits. The engineering controls also need to keep gas, vapour or dust concentrations below any lower explosive limits. Use explosion-proof ventilation equipment.

Individual protection measures

| Conforms to Regulation (EC) No. 1907/2006 (REACH), Au | nnex II, as amended by Commission Regulation (EU) |
|---|---|
| 2020/878 | |

| Code : 00346494 SIGMAFAST 278 BASE BASE | Date of issue/Date of revision : 23 October 2023 |
|--|---|
| | e controls/personal protection |
| Hygiene measures | : Wash hands, forearms and face thoroughly after handling chemical products, before eating, smoking and using the lavatory and at the end of the working period. Appropriate techniques should be used to remove potentially contaminated clothing. Contaminated work clothing should not be allowed out of the workplace. Wash contaminated clothing before reusing. Ensure that eyewash stations and safety showers are close to the workstation location. |
| Eye/face protection | : Chemical splash goggles and face shield. Use eye protection according to EN 166. |
| Skin protection | |
| Hand protection | : Chemical-resistant, impervious gloves complying with an approved standard should be worn at all times when handling chemical products if a risk assessment indicates this is necessary. Considering the parameters specified by the glove manufacturer, check during use that the gloves are still retaining their protective properties. It should be noted that the time to breakthrough for any glove material may be different for different glove manufacturers. In the case of mixtures, consisting of several substances, the protection time of the gloves cannot be accurately estimated. When prolonged or frequently repeated contact may occur, a glove with a protection class of 6 (breakthrough time greater than 480 minutes according to EN 374) is recommended. When only brief contact is expected, a glove with a protection class of 2 or higher (breakthrough time greater than 30 minutes according to EN 374) is recommended. The user must check that the final choice of type of glove selected for handling this product is the most appropriate and takes into account the particular conditions of use, as included in the user's risk assessment. |
| Gloves | : butyl rubber |
| Body protection | : Personal protective equipment for the body should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product. When there is a risk of ignition from static electricity, wear anti- static protective clothing. For the greatest protection from static discharges, clothing should include anti-static overalls, boots and gloves. Refer to European Standard EN 1149 for further information on material and design requirements and test methods. |
| Other skin protection | Appropriate footwear and any additional skin protection measures should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product. |
| Respiratory protection | : Respirator selection must be based on known or anticipated exposure levels, the hazards of the product and the safe working limits of the selected respirator. If workers are exposed to concentrations above the exposure limit, they must use appropriate, certified respirators. Use a properly fitted, air-purifying or air-fed respirator complying with an approved standard if a risk assessment indicates this is necessary. Wear a respirator conforming to EN140. Filter type: organic vapour (Type A) and particulate filter P3 |
| Environmental exposure controls | : Emissions from ventilation or work process equipment should be checked to ensure they comply with the requirements of environmental protection legislation. In some cases, fume scrubbers, filters or engineering modifications to the process equipment will be necessary to reduce emissions to acceptable levels. |

SECTION 9: Physical and chemical properties

The conditions of measurement of all properties are at standard temperature and pressure unless otherwise indicated.

| English (GB) | Ireland | 12/22 |
|-----------------------------|---------------------------------|-------|
| Odour threshold | : Not available. | |
| Odour | : Aromatic. | |
| Colour | : Various | |
| Physical state | : Liquid. | |
| <u>Appearance</u> | | |
| 3.1 Information on basic pl | nysical and chemical properties | |

| Code : 00346494 SIGMAFAST 278 BASE BASE L | | Dat | e of issue | e/Date o | f revision | : 2 | 3 October | 2023 |
|--|-----|--|---|---|---|----------------|--------------------------|--------------------------|
| SECTION 9: Physical a | nd | chemical pro | perties | | | | | |
| Melting point/freezing point | | May start to solidify a based on data for th Weighted average: - | e following | g ingredi | ent: bis-[4-(2, | | | |
| Initial boiling point and boiling range | | >37.78°C | , | , | | | | |
| Flammability Upper/lower flammability or explosive limits | | Not available. Greatest known range: Lower: 1.48% Upper: 13.74% (1-methoxy-2-propanol) | | | | | | |
| Flash point | : | Closed cup: 38°C | | | | | | |
| Auto-ignition temperature | : | | | | | | | |
| | ſ | Ingredient name | | °C | °F | | Method | |
| | | 1-methoxy-2-propanol | | 270 | 518 | | | |
| Decomposition temperature | : : | Stable under recomi | mended s | torage a | nd handling c | onditions | s (see Sec | tion 7). |
| pH | : 1 | Not applicable. insol | uble in wa | iter. | - | | | · |
| Viscosity | : 1 | Kinematic (40°C): >2 | 21 mm²/s | | | | | |
| Solubility(ies) | : | | | | | | | |
| Media | | Result | | | | | | |
| cold water | | Not soluble | | | | | | |
| Partition coefficient: n-octanol/ water | /: | Not applicable. | | | | | | |
| Vapour pressure | : | | | | | | | |
| | | | Vapou | ır Press | ure at 20°C | Vap | our press | sure at 50°C |
| | | | | | Mathead | | kPa | Method |
| | | Ingredient name | mm Hg | kPa | Method | mm Hg | кга | method |
| | | Ingredient name | mm Hg 9.3 | kPa 1.2 | | | KF d | |
| Evaporation rate | : | _ | 9.3 | 1.2 | | Hg | | |
| - | : | ethylbenzene Highest known value | 9.3 | 1.2 | | Hg | | |
| Relative density | : | ethylbenzene Highest known value butyl acetate | 9.3 9.3 e: 0.84 (et | 1.2 hylbenze ir = 1) (1 | ene) Weighte | Hg d averag | je: 0.79co | mpared with |
| Relative density Vapour density | | ♥fnylbenzene Highest known value butyl acetate 1.7 ✔ighest known value | 9.3 e: 0.84 (et e: 11.7 (A 3.31 (Air = not explos | 1.2 hylbenze ir = 1) (l = 1) sive, but | ene) Weighte bis-[4-(2,3-ep | Hg d averag | je: 0.79co xi)phenyl] | mpared with propane). |
| Relative density Vapour density Explosive properties | | effylbenzene Highest known value butyl acetate 1.7 Highest known value Weighted average: 8 The product itself is | 9.3 9.3 e: 0.84 (et e: 11.7 (A 3.31 (Air = not explos air is poss | 1.2 hylbenze ir = 1) ((= 1) sive, but ible. | ene) Weighte bis-[4-(2,3-ep the formation | Hg d averag | je: 0.79co xi)phenyl] | mpared with propane). |
| Relative density Vapour density Explosive properties Oxidising properties | | ethylbenzene Highest known value butyl acetate 1.7 Highest known value Weighted average: 8 The product itself is vapour or dust with a | 9.3 9.3 e: 0.84 (et e: 11.7 (A 3.31 (Air = not explos air is poss | 1.2 hylbenze ir = 1) ((= 1) sive, but ible. | ene) Weighte bis-[4-(2,3-ep the formation | Hg d averag | je: 0.79co xi)phenyl] | mpared with propane). |
| Evaporation rate Relative density Vapour density Explosive properties Oxidising properties Particle characteristics Median particle size | | ethylbenzene Highest known value butyl acetate 1.7 Highest known value Weighted average: 8 The product itself is vapour or dust with a | 9.3 9.3 e: 0.84 (et e: 11.7 (A 3.31 (Air = not explos air is poss | 1.2 hylbenze ir = 1) ((= 1) sive, but ible. | ene) Weighte bis-[4-(2,3-ep the formation | Hg d averag | je: 0.79co xi)phenyl] | mpared with propane). |
| Relative density Vapour density Explosive properties Oxidising properties Particle characteristics | | ethylbenzene Highest known value butyl acetate 1.7 Highest known value Weighted average: 8 Weighted average: 8 The product itself is vapour or dust with a Product does not pre | 9.3 9.3 e: 0.84 (et e: 11.7 (A 3.31 (Air = not explos air is poss | 1.2 hylbenze ir = 1) ((= 1) sive, but ible. | ene) Weighte bis-[4-(2,3-ep the formation | Hg d averag | je: 0.79co xi)phenyl] | mpared with propane). |

SECTION 10: Stability and reactivity

| English (GB) | Ireland | 13/22 |
|--|--|-----------------------|
| 10.3 Possibility of hazardous reactions | : Under normal conditions of storage and use, hazardous reaction | s will not occur. |
| 10.2 Chemical stability | : The product is stable. | |
| 10.1 Reactivity | : No specific test data related to reactivity available for this product | t or its ingredients. |

| Code : 00346494 | Date of issue/Date of revision | : 23 October 2023 |
|------------------------------------|--------------------------------|-------------------|
| SIGMAFAST 278 BASE BASE L | | |
| SECTION 10: Stability and reactive | vity | |

| 10.4 Conditions to avoid | : | When exposed to high temperatures may produce hazardous decomposition products. Refer to protective measures listed in sections 7 and 8. |
|--|---|---|
| 10.5 Incompatible materials | : | Keep away from the following materials to prevent strong exothermic reactions: oxidising agents, strong alkalis, strong acids. |
| 10.6 Hazardous decomposition products | : | Depending on conditions, decomposition products may include the following materials: carbon oxides halogenated compounds metal oxide/oxides |

SECTION 11: Toxicological information

11.1 Information on hazard classes as defined in Regulation (EC) No 1272/2008 Acute toxicity

| Product/ingredient name | Result | Species | Dose | Exposure |
|--|---------------------------------|---------|-------------|----------|
| s-[4-(2,3-epoxipropoxi)phenyl]propane | LD50 Dermal | Rabbit | 23000 mg/kg | - |
| | LD50 Oral | Rat | 15000 mg/kg | - |
| xylene | LD50 Dermal | Rabbit | 1.7 g/kg | - |
| - | LD50 Oral | Rat | 4.3 g/kg | - |
| 4-nonylphenol, branched | LD50 Dermal | Rabbit | 2.14 g/kg | - |
| | LD50 Oral | Rat | 1300 mg/kg | - |
| 1-methoxy-2-propanol | LC50 Inhalation Vapour | Rat | >7000 ppm | 6 hours |
| | LD50 Dermal | Rabbit | 13 g/kg | - |
| | LD50 Oral | Rat | 5.2 g/kg | - |
| ethylbenzene | LC50 Inhalation Vapour | Rat | 17.8 mg/l | 4 hours |
| | LD50 Dermal | Rabbit | 17.8 g/kg | - |
| | LD50 Oral | Rat | 3.5 g/kg | - |
| oxirane, mono[(C12-14-alkyloxy)methyl] derivs. | LD50 Oral | Rat | 17100 mg/kg | - |
| trizinc bis(orthophosphate) | LC50 Inhalation Dusts and mists | Rat | >5.7 mg/l | 4 hours |
| | LD50 Oral | Rat | >5000 mg/kg | - |
| propylidynetrimethanol | LD50 Dermal | Rabbit | 10 g/kg | - |
| | LD50 Oral | Rat | 14000 mg/kg | - |
| maleic anhydride | LD50 Dermal | Rabbit | 2620 mg/kg | - |
| | LD50 Oral | Rat | 400 mg/kg | - |

Conclusion/Summary : There are no data available on the mixture itself.

Irritation/Corrosion

| Product/ingredient name | Result | Species | Score | Exposure | Observation |
|---------------------------------------|------------------------------------|---------|-------|-----------------|-------------|
| s-[4-(2,3-epoxipropoxi)phenyl]propane | Eyes - Mild irritant | Rabbit | - | 24 hours | - |
| | Eyes - Redness of the conjunctivae | Rabbit | 0.4 | 24 hours | - |
| | Skin - Oedema | Rabbit | 0.5 | 4 hours | - |
| | Skin - Erythema/Eschar | Rabbit | 0.8 | 4 hours | - |
| | Skin - Mild irritant | Rabbit | - | 4 hours | - |
| xylene | Skin - Moderate irritant | Rabbit | - | 24 hours 500 mg | - |
| 4-nonylphenol, branched | Skin - Erythema/Eschar | Rabbit | 4 | - | - |

| Conclusion/Summary | |
|--------------------|--|
| Skin | : There are no data available on the mixture itself. |
| Eyes | : There are no data available on the mixture itself. |
| Respiratory | : There are no data available on the mixture itself. |
| Sensitisation | |

English (GB)

| Code | : 00346494 | Date of issue/Date of revision | : 23 October 2023 |
|-----------|------------|--------------------------------|-------------------|
| 010145407 | | | |

SIGMAFAST 278 BASE BASE L

SECTION 11: Toxicological information

| Product/ingre | dient name | Route of exposure | Species | Result |
|--|--|---------------------|----------------------------|---------------|
| | | Mouse Guinea pig | Sensitising Sensitising | |
| Conclusion/Summary | | | - | |
| Skin | : There are no data avail | able on the mixtur | e itself. | |
| Respiratory | : There are no data avail | able on the mixtur | e itself. | |
| Mutagenicity | | | | |
| Conclusion/Summary | : There are no data available on the mixture itself. | | | |
| Carcinogenicity | | | | |
| Conclusion/Summary | : There are no data available on the mixture itself. | | | |
| Reproductive toxicity | | | | |
| Conclusion/Summary : There are no data available on the mixture itself. | | | | |
| Teratogenicity | | | | |
| Conclusion/Summary : There are no data available on the mixture itself. | | | | |
| Specific target organ toxi | <u>city (single exposure)</u> | | | |
| Product/in | gredient name | Category | Route of exposure | Target organs |

Specific target organ toxicity (repeated exposure)

| Product/ingredient name | Category | Route of exposure | Target organs |
|---|------------|-------------------|--------------------|
| crystalline silica, respirable powder (<10 microns) | Category 1 | inhalation | - |
| ethylbenzene | Category 2 | - | hearing organs |
| maleic anhydride | Category 1 | inhalation | respiratory system |

Category 3

Category 3

-

-

Aspiration hazard

1-methoxy-2-propanol

xylene

| Produ | ict/ingredient name | Result |
|--|---|--|
| xylene ethylbenzene | | ASPIRATION HAZARD - Category 1 ASPIRATION HAZARD - Category 1 |
| Information on likely routes of exposure | : Not available. | |
| Potential acute health ef | <u>fects</u> | |
| Inhalation | : No known significant ef | ffects or critical hazards. |
| Ingestion | : Corrosive to the digestive | ve tract. Causes burns. |
| Skin contact | : Causes severe burns. | Defatting to the skin. May cause an allergic skin reaction. |
| Eye contact | : Causes serious eye dar | mage. |
| Symptoms related to the | e physical, chemical and toxic | cological characteristics |
| Inhalation | : Adverse symptoms may reduced foetal weight increase in foetal death skeletal malformations | |

Respiratory tract irritation

Narcotic effects

| Code : 00346494 SIGMAFAST 278 BASE BASE | Date of issue/Date of revision: 23 October 2023L |
|--|---|
| SECTION 11: Toxicol | ogical information |
| Ingestion | : Adverse symptoms may include the following: stomach pains reduced foetal weight increase in foetal deaths skeletal malformations |
| Skin contact | : Adverse symptoms may include the following: pain or irritation redness dryness cracking blistering may occur reduced foetal weight increase in foetal deaths skeletal malformations |
| Eye contact | : Adverse symptoms may include the following: pain watering redness |
| | cts as well as chronic effects from short and long-term exposure |
| Short term exposure | |
| Potential immediate effects | : Not available. |
| Potential delayed effects | : Not available. |
| <u>Long term exposure</u> | |
| Potential immediate effects | : Not available. |
| Potential delayed effects | : Not available. |
| Potential chronic health effe | ects |
| Not available. | |
| Conclusion/Summary | : Not available. |
| General | May cause damage to organs through prolonged or repeated exposure. Prolonged or repeated contact can defat the skin and lead to irritation, cracking and/or dermatitis. Once sensitized, a severe allergic reaction may occur when subsequently exposed to very low levels. |
| Carcinogenicity | : No known significant effects or critical hazards. |
| Mutagenicity | : No known significant effects or critical hazards. |
| Reproductive toxicity | : Suspected of damaging fertility. Suspected of damaging the unborn child. |
| Other information | : Not available. |

Causes digestive tract burns. Prolonged or repeated contact may dry skin and cause irritation. Sanding and grinding dusts may be harmful if inhaled. Repeated exposure to high vapor concentrations may cause irritation of the respiratory system and permanent brain and nervous system damage. Inhalation of vapour/aerosol concentrations above the recommended exposure limits causes headaches, drowsiness and nausea and may lead to unconsciousness or death. Avoid contact with skin and clothing.

11.2 Information on other hazards

11.2.1 Endocrine disrupting properties

Not available.

11.2.2 Other information

Not available.

Code : 00346494 SIGMAFAST 278 BASE BASE L Date of issue/Date of revision

: 23 October 2023

SECTION 12: Ecological information

12.1 Toxicity

| Product/ingredient name | Result | Species | Exposure |
|--|---------------------------|--------------------------|----------|
| bis-[4-(2,3-epoxipropoxi)phenyl]propane | Acute LC50 1.8 mg/l Fresh | Daphnia - <i>daphnia</i> | 48 hours |
| | water | magna | |
| | Chronic NOEC 0.3 mg/l | Daphnia | 21 days |
| 4-nonylphenol, branched | Acute EC50 0.044 mg/l | Crustaceans - Moina | 48 hours |
| | _ | macrocopa | |
| | Acute LC50 0.221 mg/l | Fish | 96 hours |
| 1-methoxy-2-propanol | Acute LC50 23300 mg/l | Daphnia | 48 hours |
| | Acute LC50 >4500 mg/l | Fish | 96 hours |
| | Fresh water | | |
| ethylbenzene | Acute EC50 1.8 mg/l Fresh | Daphnia | 48 hours |
| • | water | | |
| | Chronic NOEC 1 mg/l Fresh | Daphnia - | - |
| | water | Ceriodaphnia dubia | |
| oxirane, mono[(C12-14-alkyloxy)methyl] derivs. | LC50 >100 mg/l | Fish | 96 hours |
| trizinc bis(orthophosphate) | Acute LC50 0.112 mg/l | Fish | 96 hours |
| | Chronic NOEC 0.026 mg/l | Fish | 30 days |
| propylidynetrimethanol | Acute LC50 >1000 mg/l | Fish | 96 hours |

Conclusion/Summary : There are no data available on the mixture itself.

12.2 Persistence and degradability

| Product/ingredient name | Test | Result | Dose | Inoculum | |
|-------------------------|------|--------------------------|------|----------|--|
| e thylbenzene | - | 79 % - Readily - 10 days | - | - | |
| Conclusion/Summary | | | | | |

Conclusion/Summary : There are no data available on the mixture itself.

| Product/ingredient name | Aquatic half-life | Photolysis | Biodegradability |
|---------------------------------------|-------------------|------------|------------------|
| s-[4-(2,3-epoxipropoxi)phenyl]propane | - | - | Not readily |
| xylene | - | - | Readily |
| ethylbenzene | - | - | Readily |

12.3 Bioaccumulative potential

| Product/ingredient name | LogPow | BCF | Potential |
|--|--------|-------------|-----------|
| vlene | 3.12 | 7.4 to 18.5 | Low |
| 4-nonylphenol, branched | 5.4 | 251.19 | Low |
| 1-methoxy-2-propanol | <1 | - | Low |
| ethylbenzene | 3.6 | 79.43 | Low |
| oxirane, mono[(C12-14-alkyloxy)methyl] derivs. | 3.77 | - | Low |
| propylidynetrimethanol | -0.47 | - | Low |
| maleic anhydride | -2.78 | - | Low |

12.4 Mobility in soil

| Soil/water partition coefficient (Koc) | : Not available. |
|--|------------------|
| Mobility | : Not available. |

12.5 Results of PBT and vPvB assessment

This mixture does not contain any substances that are assessed to be a PBT or a vPvB.

| Engli | sh (GB) | Ireland | 17/22 |
|-------|---------|---------|-------|
| | (| | == |

| Code | : 00346494 | Date of issue/Date of revision | : 23 October 2023 |
|-----------|-----------------|--------------------------------|-------------------|
| SIGMAFAST | 278 BASE BASE L | | |

SECTION 12: Ecological information

12.6 Endocrine disrupting properties

May cause endocrine disruption.

12.7 Other adverse effects

No known significant effects or critical hazards.

SECTION 13: Disposal considerations

The information in this section contains generic advice and guidance. The list of Identified Uses in Section 1 should be consulted for any available use-specific information provided in the Exposure Scenario(s).

13.1 Waste treatment methods

Product

```
    Methods of disposal
    The generation of waste should be avoided or minimised wherever possible. Disposal of this product, solutions and any by-products should at all times comply with the requirements of environmental protection and waste disposal legislation and any regional local authority requirements. Dispose of surplus and non-recyclable products via a licensed waste disposal contractor. Waste should not be disposed of untreated to the sewer unless fully compliant with the requirements of all authorities with jurisdiction.
    Hazardous waste
    Yes.
```

European waste catalogue (EWC)

| Waste code | Waste designation |
|------------|---|
| 08 01 11* | waste paint and varnish containing organic solvents or other hazardous substances |

Packaging

Methods of disposal

: The generation of waste should be avoided or minimised wherever possible. Waste packaging should be recycled. Incineration or landfill should only be considered when recycling is not feasible.

| Type of packaging | European waste catalogue (EWC) | | |
|---------------------|--|---|--|
| Container | 15 01 06 | mixed packaging | |
| Special precautions | taken when I Empty conta residues may Do not cut, w | I and its container must be disposed of in a safe way. Care should be nandling emptied containers that have not been cleaned or rinsed out. iners or liners may retain some product residues. Vapour from product y create a highly flammable or explosive atmosphere inside the container. yeld or grind used containers unless they have been cleaned thoroughly void dispersal of spilt material and runoff and contact with soil, waterways, ewers. | |

14. Transport information

| | ADR/RID | ADN | IMDG | ΙΑΤΑ |
|------------------------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------------|
| 14.1 UN number or ID number | UN3470 | UN3470 | UN3470 | UN3470 |
| 14.2 UN proper shipping name | PAINT, CORROSIVE, FLAMMABLE | PAINT, CORROSIVE, FLAMMABLE | PAINT, CORROSIVE, FLAMMABLE | PAINT, CORROSIVE, FLAMMABLE |
| 14.3 Transport hazard class(es) | 8 (3) | 8 (3) | 8 (3) | 8 (3) |
| 14.4 Packing group | II | II | II | II |
| English (G | B) | Irela | and | 18/22 |

| | 1 278 BASE BASE L | | | |
|------|-------------------|--------------------------------|-------------------|--|
| Code | : 00346494 | Date of issue/Date of revision | : 23 October 2023 | |

sport miormation

| | • | | | | |
|----------------------------------|-----------------|-----------------|--|---|--|
| 14.5 Environmental hazards | Yes. | Yes. | Yes. | Yes. The environmentally hazardous substance mark is not required. | |
| Marine pollutant substances | Not applicable. | Not applicable. | (bis-[4- (2,3-epoxipropoxi) phenyl]propane, 4-nonylphenol, branched) | Not applicable. | |

Additional information

| ADR/RID | : The environmentally hazardous substance mark is not required when transported in sizes of ≤5 L or ≤5 kg. |
|--------------------------|---|
| Tunnel code | : (D/E) |
| ADN | : The environmentally hazardous substance mark is not required when transported in sizes of ≤5 L or ≤5 kg. |
| IMDG | : The marine pollutant mark is not required when transported in sizes of $\leq 5 \text{ L}$ or $\leq 5 \text{ kg}$. |
| ΙΑΤΑ | : The environmentally hazardous substance mark may appear if required by other transportation regulations. |
| 14.6 Special pre user | cautions for : Transport within user's premises: always transport in closed containers that are upright and secure. Ensure that persons transporting the product know what to do in the event of an accident or spillage. |

14.7 Maritime transport in : Not applicable. bulk according to IMO instruments

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture EU Regulation (EC) No. 1907/2006 (REACH)

Annex XIV - List of substances subject to authorisation

Annex XIV

None of the components are listed.

Substances of very high concern

| Intrinsic property | Ingredient name | Status | Reference number | Date of revision |
|---|--|-----------|---------------------|------------------|
| Endocrine disrupting properties for environment | 4-nonylphenol, branched and linear substances with a linear and/or branched alkyl chain with a carbon number of 9 covalently bound in position 4 to phenol, covering also UVCB- and well-defined substances which include any of the individual isomers or a combination thereof | Candidate | ED/169/2012 | 12/19/2012 |

Annex XVII - Restrictions : Not applicable. on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles

| English | (GB) |
|---------|------|
|---------|------|

| Code | : 00346494 | Date of issue/Date of revision | : 23 October 2023 |
|-----------|-----------------|--------------------------------|-------------------|
| SIGMAFAST | 278 BASE BASE L | | |
| | | | |

SECTION 15: Regulatory information

Explosive precursors : Not applicable.

Ozone depleting substances (1005/2009/EU)

Not listed.

Seveso Directive

This product is controlled under the Seveso Directive.

| Da | nge | er c | rite | eria |
|----|-----|------|------|------|
| | | | | |

Category

P5c

E1

| Product/ingredient name | List name | Name on list | Classification | Notes |
|-------------------------|-----------|--|----------------|-------|
| Quartz (SiO2) | | silica, crystalline respirable dust | Carc. | - |

15.2 Chemical safety

: No Chemical Safety Assessment has been carried out.

assessment

SECTION 16: Other information

Indicates information that has changed from previously issued version.

Abbreviations and acronyms

ATE = Acute Toxicity Estimate

CLP = Classification, Labelling and Packaging Regulation [Regulation (EC) No. 1272/2008]

DNEL = Derived No Effect Level

EUH statement = CLP-specific Hazard statement

PNEC = Predicted No Effect Concentration

RRN = REACH Registration Number

PBT = Persistent, Bioaccumulative and Toxic

vPvB = Very Persistent and Very Bioaccumulative

ADR = The European Agreement concerning the International Carriage of Dangerous Goods by Road

ADN = European Provisions concerning the International Carriage of Dangerous Goods by Inland Waterway

IMDG = International Maritime Dangerous Goods

IATA = International Air Transport Association

Procedure used to derive the classification according to Regulation (EC) No. 1272/2008 [CLP/GHS]

| Classification | ssification Justification | |
|-------------------------|---------------------------|--|
| Flam. Liq. 3, H226 | On basis of test data | |
| Skin Corr. 1B, H314 | Calculation method | |
| Eye Dam. 1, H318 | Calculation method | |
| Skin Sens. 1, H317 | Calculation method | |
| Repr. 2, H361fd | Calculation method | |
| STOT RE 2, H373 | Calculation method | |
| Aquatic Acute 1, H400 | Calculation method | |
| Aquatic Chronic 1, H410 | Calculation method | |

Full text of abbreviated H statements

| Code : 00346494 SIGMAFAST 278 BASE BASE L | Date of issue/Date of revision: 23 October 2023 | | | |
|--|---|--|--|--|
| SECTION 16: Other information | | | | |
| H225 | Highly flammable liquid and vapour. | | | |
| H226 | Flammable liquid and vapour. | | | |
| H302 | Harmful if swallowed. | | | |
| H304 | May be fatal if swallowed and enters airways. | | | |
| H312 | Harmful in contact with skin. | | | |
| H314 | Causes severe skin burns and eye damage. | | | |
| | Causes severe skin burns and eye damage. Causes skin irritation. | | | |
| H315 | | | | |
| H317 | May cause an allergic skin reaction. | | | |
| H318 | Causes serious eye damage. | | | |
| H319 | Causes serious eye irritation. | | | |
| H332 | Harmful if inhaled. | | | |
| H334 | May cause allergy or asthma symptoms or breathing difficulties if | | | |
| | inhaled. | | | |
| H335 | May cause respiratory irritation. | | | |
| H336 | May cause drowsiness or dizziness. | | | |
| H361 | Suspected of damaging fertility or the unborn child. | | | |
| | | | | |
| H361fd | Suspected of damaging fertility. Suspected of damaging the unborn | | | |
| | child. | | | |
| H372 | Causes damage to organs through prolonged or repeated exposure | | | |
| H373 | May cause damage to organs through prolonged or repeated | | | |
| | exposure. | | | |
| H400 | Very toxic to aquatic life. | | | |
| H410 | Very toxic to aquatic life with long lasting effects. | | | |
| H411 | Toxic to aquatic life with long lasting effects. | | | |
| H412 | Harmful to aquatic life with long lasting effects. | | | |
| EUH071 | Corrosive to the respiratory tract. | | | |
| Full text of classifications [CLP/GHS] | | | | |
| | | | | |
| Acute Tox. 4 | ACUTE TOXICITY - Category 4 | | | |
| Aquatic Acute 1 | SHORT-TERM (ACUTE) AQUATIC HAZARD - Category 1 | | | |
| Aquatic Chronic 1 | LONG-TERM (CHRONIC) AQUATIC HAZARD - Category 1 | | | |
| Aquatic Chronic 2 | LONG-TERM (CHRONIC) AQUATIC HAZARD - Category 2 | | | |
| Aquatic Chronic 3 | LONG-TERM (CHRONIC) AQUATIC HAZARD - Category 3 | | | |
| Asp. Tox. 1 | ASPIRATION HAZARD - Category 1 | | | |
| Eye Dam. 1 | SERIOUS EYE DAMAGE/EYE IRRITATION - Category 1 | | | |
| Eye Irrit. 2 | SERIOUS EYE DAMAGE/EYE IRRITATION - Category 2 | | | |
| | | | | |
| Flam. Liq. 2 | FLAMMABLE LIQUIDS - Category 2 | | | |
| Flam. Liq. 3 | FLAMMABLE LIQUIDS - Category 3 | | | |
| Repr. 2 | REPRODUCTIVE TOXICITY - Category 2 | | | |
| Resp. Sens. 1 | RESPIRATORY SENSITISATION - Category 1 | | | |
| Skin Corr. 1B | SKIN CORROSION/IRRITATION - Category 1B | | | |
| Skin Irrit. 2 | SKIN CORROSION/IRRITATION - Category 2 | | | |
| Skin Sens. 1 | SKIN SENSITISATION - Category 1 | | | |
| Skin Sens. 1A | SKIN SENSITISATION - Category 1A | | | |
| Skin Sens. 1B | SKIN SENSITISATION - Category 1B | | | |
| STOT RE 1 | SPECIFIC TARGET ORGAN TOXICITY - REPEATED EXPOSURE | | | |
| | Category 1 | | | |
| | | | | |
| STOT RE 2 | SPECIFIC TARGET ORGAN TOXICITY - REPEATED EXPOSURE | | | |
| | Category 2 | | | |
| STOT SE 3 | SPECIFIC TARGET ORGAN TOXICITY - SINGLE EXPOSURE - | | | |
| | Category 3 | | | |
| listony | | | | |
| <u>listory</u> | | | | |
| Date of issue/ Date of : 23 Octob evision | er 2023 | | | |

English (GB)

Ireland

| Code : 00346 SIGMAFAST 278 BAS | | Date of issue/Date of revision | : 23 October 2023 | |
|-----------------------------------|-------|--------------------------------|-------------------|--|
| SECTION 16: Other information | | | | |
| Prepared by | : EHS | | | |
| Version | : 4 | | | |

Disclaimer

The information contained in this data sheet is based on present scientific and technical knowledge. The purpose of this information is to draw attention to the health and safety aspects concerning the products supplied by us, and to recommend precautionary measures for the storage and handling of the products. No warranty or guarantee is given in respect of the properties of the products. No liability can be accepted for any failure to observe the precautionary measures described in this data sheet or for any misuse of the products.